Lipids & metabolic liver disease
A low‐energy total diet replacement program demonstrates a favorable safety profile and improves liver disease severity in nonalcoholic steatohepatitis
An erratum to this article was published (Obesity (Silver Spring), Oct 2023 ↗)
Authors' conclusion
The intervention demonstrates high adherence, favorable safety profile, and promising efficacy as a treatment for NASH.
Study context
- Population
- Adults with nonalcoholic steatohepatitis (NASH), fibrosis and obesity14 completed
- Participants
- 16 adults
- Comparison
- Low-energy (880 kcal/d) total diet replacement for 12 weeks, then stepped food reintroduction for 12 weeks; vs baseline
- Total diet replacementn = 16
- Outcome
- Liver disease severity vs baseline
- Follow-up
- 24 weeks
Methodological details24-week, blinded outcome assessment, remote dietetic support
- 24-week
- Blinded outcome assessment
- Remote dietetic support
Main finding
As reported in the abstract
- MRI-PDFF reduction vs baseline
- 13.1% (95% CI: 8.9%-16.7%)
- cT1 reduction vs baseline
- 159 milliseconds (95% CI: 108-216.5)
- MRE liver stiffness reduction vs baseline
- 0.4 kPa (95% CI: 0.1-0.8)
- VCTE liver stiffness reduction vs baseline
- 3.9 kPa (95% CI: 2.6-7.2)
- Clinically relevant reduction in MRI-PDFF (≥30%)
- 93%
- Clinically relevant reduction in cT1 (≥88 milliseconds)
- 77%
- Clinically relevant reduction in MRE liver stiffness (≥19%)
- 57%
- Clinically relevant reduction in VCTE liver stiffness (≥19%)
- 93%
Further findings
Weight loss · 24 weeks
- Weight loss
- 15% (95% CI: 11.2%-18.6%)
Completion
- Completed the intervention
- 14 (87.5%)
Safety
- Serious intervention-related adverse events
- 0
- Liver biochemical markers improved
Original publication
A low‐energy total diet replacement program demonstrates a favorable safety profile and improves liver disease severity in nonalcoholic steatohepatitis. Obesity (Silver Spring). Published 27 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →